We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Astellas Pharma Europe Appoints Ken Jones as President and CEO
News

Astellas Pharma Europe Appoints Ken Jones as President and CEO

Astellas Pharma Europe Appoints Ken Jones as President and CEO
News

Astellas Pharma Europe Appoints Ken Jones as President and CEO

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Astellas Pharma Europe Appoints Ken Jones as President and CEO"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In 2009-10, a challenging time for the pharmaceutical industry as a whole, APEL achieved €1.4 billion in sales, representing growth of 9% against the previous year’s €1.3 billion  and forecasting 1.5 billion (10%) in the forecast FY2010.  As Mr Jones takes up leadership, APEL is well positioned to achieve the goals defined in its mid-term strategy: reinforcement of category leadership in Transplantation and Urology; franchise expansion in Pain Management, Anti-Infectives and Oncology, and the delivery of treatments in areas where unmet medical needs still exist. Two strategic alliances announced in February 2011 demonstrate Astellas’ commitment to these goals: APEL has entered into a partnership agreement with Optimer Pharmaceuticals Inc. for the development and commercialisation in Europe and selected other countries of fidaxomicin for the treatment of clostridium difficile infection. In addition, Astellas is partnering with AVEO Pharmaceuticals Inc (AVEO). to commercialise and develop tivozanib which is currently under investigation in clinical trials for the treatment of renal cell carcinoma as well as a broad range of other cancers.

Mr Jones, President and CEO of Astellas Pharma Europe Ltd., commented:

“I am delighted and honoured to be taking on this new role and I look forward to building on Astellas Pharma Europe’s considerable achievements. In spite of the tough market conditions which the industry is facing, we’re in a strong position and have clear strategies for growth through expanding and developing our core franchises. Having the stability of a large company combined with the agility of a smaller operation gives us a real competitive advantage in terms of our ability to achieve these goals by responding rapidly to opportunities in the market. Our recent partnerships with Optimer and AVEO are good examples of this and have enriched our Anti-Infectives and Oncology pipelines significantly. I hope to continue to drive solid growth for Astellas Pharma Europe in the years ahead.”

Mr Jones joined the company (then Yamanouchi) in January 2003 as Vice President, European Marketing and in 2005, when Fujisawa and Yamanouchi merged to produce Astellas, was promoted to Senior Vice President, Sales, Marketing and Medical. Previously, Jones spent 16 years with Allergan, Inc. (“Allergan”), holding senior international marketing positions across the US, Europe and Japan. His career began as a management associate with SmithKline Beckman in Philadelphia, followed by increasingly senior roles in Allergan, working in France, Japan, UK and at Allergan HQ in Irvine, California.  Jones holds an MSc from the London Business School, a BA from Occidental College, Eagle Rock (and he attended Waseda University in Japan as part of a foreign exchange student programme).  He speaks Japanese and French fluently.

Advertisement